• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® ADPR Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • CD38 Assay System
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human CD38 Enzyme
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay System
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • p97 Assays – Application
      • Ketohexokinase Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
      • WRN Exonuclease Assays – Application
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Transcreener® ADP2 Assay Delivers Precise Measurement of Functional MAPK14 Residence Time

by Bellbrook Labs / Monday, 01 May 2023 / Published in Emerging Targets, HTS Assays, Innate Immunity, Products, Success Stories
Calculating MAPK14 Residence Time

Researchers at the University of Tubingen use Transcreener to uncover how residence time works on a molecular level with p38α MAPK Inhibitors – Many factors affect the effectiveness of ligand-substrate or drug-target interactions. Conformational docking and stearic considerations help inform optimal “fits.” Ligand moiety solubility, both in free and bound forms, is also a consideration due to the omnipresent influence of water. Once upon a time, association/dissociation measurements were all the rage. The lower the KD, the better. After all, if your ligand “sticks” more avidly to its target, shouldn’t that make it more effective? However, better docking does not necessarily mean longer docking. As rational drug design has evolved, total ligand residence time has been recognized as yet another factor in pharmacological efficacy.

Residence time is the time a drug remains bound to its target before dissociating; it is the reciprocal of dissociation rate (koff). For certain applications, remaining target-bound interactions for long periods, even after physiological clearance, can be advantageous.1,2

One commonly used method for measuring residence time is Surface Plasmon Residence (SPR), where proteins are bound to the surface of a chip and exposed to a stream of ligand. Jump dilution is an alternative method that measures the recovery of enzyme activity as the inhibitor dissociates.3

The Transcreener ADP2 FP (Fluorescence Polarization) assay can be used to measure residence times for kinase inhibitors by jump dilution because it allows continuous monitoring of ADP formation. In this method, the drug and target enzyme are incubated together to form the drug-target complex, and this complex is then diluted to dissociate. The ADP assay monitors the recovery of enzyme activity as the drug-target complex dissociates.4 

cGAMP Jump Dilution Schematic

 

MAPK14 Residence Time

p38-alpha MAPK (MAPK14) is a member of the MAPK family of proteins, critical for development and signaling under nominal conditions. MAPK14 plays an important role in response to inflammatory cytokines, cellular stress, and apoptosis. Its dysregulation has been implicated in inflammatory disorders, neurodegenerative disease, adverse cardiovascular remodeling, and cancer. While MAPK14 has been extensively studied and many inhibitors have been found, none have been approved for routine clinical use.5

Pantsar et al (2022) set out to explore the residence time parameters associated with molecular inhibitors of MAPK14. Understanding the factors affecting inhibitor residence time should enhance the drug optimization process.6

Utilizing various measures of IC50 and the two methods for measuring residence time, the authors assessed three different inhibitors with different structures and residence times. Two of the larger inhibitors (1 and 2) possessed similar low nM IC50 inhibition. A smaller, short-acting inhibitor was also profiled for comparison. Overall, their results showed that inhibitor residence time was enhanced by greater target conformational stability, less ligand solvent exposure, more buried ligand surface area, and a higher energy barrier to ligand resolvation.6 Focusing on differences in residence time measurements using the two methods, the authors assert that the jump dilution method with the Transcreener ADP assay may be more accurate than SPR because it measures inhibitor dissociation under more physiologically relevant biological conditions.6

Implications for Future Research

Finding clinically useful inhibitors of MAPK14 has been extraordinarily difficult. Appropriate MAPK14 modulation will likely be more useful for treatment than complete inhibition. In this case, precise measurement of the factors that affect MAPK14 residence time is crucial for designing new drugs.6

While SPR has been extensively used to measure residence time, it requires tethering proteins to a planar surface, which is likely to reduce their conformational freedom. On the other hand, the jump dilution method with the Transcreener ADP Assay allows ligands and targets to freely associate in solution and uses measurements of actual catalytic activity to determine functional residence time.3,4

Learn More About The Transcreener ADP Assay

References

1. Di Cera, E. (2020) Mechanisms of ligand binding. Biophys. Rev. 1(1): 011303. Review. https://doi.org/10.1063/5.0020997
2. Copeland, R. (2016) The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov. 2016 Feb;15(2):87-95. https://doi.org/10.1038/nrd.2015.18.
3. Copeland RA. Drug–Target Residence Time. Evaluation of Enzyme Inhibitors in Drug Discovery: John Wiley & Sons, Inc.; 2013. p. 287-344.
4. Kumar, M. and Lowery, R.G. (2017) A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener ADP Assay. SLAS Discovery, 22(7), 915-922. https://doi.org/10.1177/2472555217695080
5. Madkour, M.M. et al. (2021) Current status and future prospects of p38α/MAPK14 kinase and its inhibitors. European Journal of Medicinal Chemistry, 213, 113216. Review. https://doi.org/10.1016/j.ejmech.2021.113216
6. Pantsar, T. et al. (2022) Decisive role of water and protein dynamics in residence time of p38 alpha MAP kinase inhibitors. Nature Communications, 13:569. https://doi.org/10.1038/s41467-022-28164-4.

Tagged under: cancer, inflammatory disease, Innate Immunity, kinase assay, Kinase Assay Kit, MAPK14, neurodegenerative disease, Residence Time, Transcreener ADP Assay

What you can read next

Could an Inhibitor of Phosphodiesterase Activity be a Treatment for Alzheimer’s?
GMP Assay for PDE Inhibitor Discovery
Using a Universal GMP Assay for PDE Research
Researcher Studying MAPK14
MAPK14 in Context

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Preview of DNA Damage Repair Webinar

    [Webinar] Targeting DNA Damage Repair for Drug Discovery Using the Transcreener ADPR® Assay

    Interested in DNA damage repair pathways for dr...
  • DDX1 as a versatile RNA Helicase

    DDX1: A Versatile RNA Helicase

    DDX1 (Dead-Box Helicase 1) belongs to the DEAD-...
  • RAB2 Transports Membrane Bound Vesicles

    Investigating RAB2 as a Vesicle Transporter & Autophagy Initiator

    RAB2 is part of the RAB family of small GTPases...
  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...

Archives

BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP